Prime Medicine, Inc. Income Statement
PRME / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Prime Medicine, Inc. reported $3M in revenue and $196M in net loss for FY2024. Revenue decreased 42.7% from FY2020 to FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $0 | $0 | $0 | $5.2M |
| SG&A Expense | $50.2M | $43.4M | $29.8M | $13.9M | $3.2M |
| R&D Expense | $155.3M | $147.9M | $86.7M | $70.5M | $3.0M |
| Operating Income | -$202.5M | -$204.8M | -$116.5M | -$84.5M | -$932.0K |
| Income Tax | $0 | -$279.0K | -$948.0K | -$486.0K | $1.9M |
| Net Income | -$195.9M | -$198.1M | -$121.8M | -$165.4M | -$3.4M |
| EPS (Basic) | -$1.65 | -$2.18 | -$4.19 | -$14.19 | -$1.91 |
| EPS (Diluted) | -$1.65 | -$2.18 | -$4.19 | -$14.19 | -$1.91 |
| Shares Outstanding | 118.6M | 91.0M | 33.9M | 13.0M | 2.6M |
| Operating Margin | - | - | - | - | -17.9% |
| Profit Margin | - | - | - | - | -65.5% |